针对阿尔茨海默氏病的BACE-1抑制剂
Kadja Luana Chagas Monteiro1, Marcone Gomes Dos Santos Alcântara1, Nathalia Monteiro Lins Freire1
1Research Group on Therapeutic Strategies - GPET, Laboratory of Synthesis and Research in Medicinal Chemistry - LSPMED, Institute of Chemistry and Biotechnology, Federal University of Alagoas, Lourival Melo Mota Avenue, 57072-970, Maceió, Alagoas, Brazil.
β-分泌酶1 (BACE-1) 抑制剂对于阿尔茨海默病 (AD) 药物开发至关重要. 本综述详细介绍了BACE-1抑制剂临床试验,化学类和AD治疗的未来前景.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 粉样β (Aβ) 积累驱动阿尔茨海默病 (AD) 的进展.
- 以前针对Aβ的治疗策略缺乏临床成功.
- 粉样级联假设强调tau蛋白,BACE-1和γ-分泌酶作为关键目标.
研究的目的:
- 审查用于阿尔茨海默病的BACE-1抑制剂的临床开发.
- 分析BACE-1抑制剂的药理动力学和药理动力学影响.
- 探索新的化学类和BACE-1抑制剂开发的未来方向.
主要方法:
- 对BACE-1抑制剂 (例如,E2609,MK8931,AZD-3293) 的临床试验数据的审查.
- 报告的药理动力学和药理动力学数据的分析.
- 检查各种类型的抑制剂:类,非类和自然存在的.
主要成果:
- BACE-1是减少Aβ生成的验证目标.
- 几种BACE-1抑制剂已经经过临床试验.
- 确定了当前抑制剂开发的局限性和经验教训.
结论:
- BACE-1 仍然是AD的药物化学中的一个有吸引力的目标.
- 了解局限性和经验教训对于未来的抑制剂开发至关重要.
- 探索新的化学类别和观点对于推进AD疗法至关重要.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
